Purpose of this Study
We are doing this study to learn more about the long-term effectiveness of an approved medicine that is prescribed for the treatment of EoE. We want to know how will dupilumab (Dupixent®) works over time when EoE patients and their doctors choose it as therapy. Dupilumab was approved by the FDA in May 2022 to treat EoE and was the first drug approved for this purpose.
Who Can Participate?
Eligibility
Adults ages 18+ who plan to start using dupilumab as a long-term therapy for EoE.
For more information, contact the study team at nicole.pavlus@duke.edu.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will give us permission to collect information from your routine doctor visits to manage your EoE. Additionally, you will have research "check-ins" with the study team approximately every 3 months for the first 6 months, and then every 6 months thereafter to answer questionnaires. You will be in the study for up to 3 years (36 months).
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
A U.S. Registry of Eosinophilic Esophagitis Patients Treated with Dupixent As Standard of Care
Principal Investigator
David
Leiman
Protocol Number
PRO00117064
NCT ID
NCT06693531
Phase
N/A
Enrollment Status
Pending Open to Enrollment